Forty-one percent of clinical research sites now name trial complexity their leading operational problem, up from 35 percent in 2025, and the number keeps climbing alongside two other pressures that grew in parallel: staffing shortages (39 percent, up from 30 percent) and contract and budget delays (37 percent, up from 31 percent). Those figures come from WCG’s 2026 Clinical Research Site Challenges Report, which surveyed more than 400 clinical research professionals. The pattern they describe is not a site execution problem. It is a design problem that arrives at sites already baked in.
The protocol data makes the design problem concrete. Sixty-six percent of sites rate protocol complexity as moderately high or very high, and Tufts Center for the Study of Drug Development data cited in the report puts the procedural volume of a typical protocol at more than 300 steps today, compared with roughly 200 a decade ago. Average Phase III protocols now generate close to six million datapoints. Meanwhile, 40 percent of sites reported taking on more trials this year, but only 26 percent added staff to cover the added workload. For smaller independent sites, 47 percent rank complexity as their top challenge, the highest share of any site type.
Budget negotiation is where the complexity tax becomes most visible in start-up timelines. Sites report that budget negotiation overall is the single largest source of start-up delay, with sites pointing to underfunded budgets and unreimbursed administrative work as key contributors, with most sites placing the full start-up window at two to four months. Forty-six percent said faster contracting and budgeting would do more to improve their performance than any other single change. Protocol amendments compound that drag: 87 percent of clinical research professionals report timeline delays from amendments, and That is weeks of unrecoverable effort per study that sponsors and CROs absorb as added cost.
The report’s argument for sponsors and CROs is straightforward: complexity that originates in protocol design or budget templates does not get cheaper once a site is running. Year-over-year WCG data shows these same three challenges have appeared consistently across prior reports, but the 2026 figures mark their sharpest simultaneous increase. The metric worth watching is the amendment rate. If sponsors begin embedding feasibility testing earlier in protocol design, amendment frequency is where the payoff will show first.
Source link: https://www.wcgclinical.com/insights/clinical-research-site-challenges-what-sponsors-and-cros-need-to-know/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
